Current Assets
Cash & Equivalents
Vertex Pharmaceuticals Cash & Equivalents increased by 8.2% to $5.5B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.5%, from $4.69B to $5.5B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 12.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests strong liquidity and capacity for investment or acquisitions, while a decrease may indicate heavy capital expenditure or cash burn.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
Biotech firms typically maintain high cash balances to fund long-term clinical trials and R&D pipelines.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.4B | $2.7B | $3.3B | $3.2B | $3.5B | $3.5B | $3.1B | $2.1B | $4.2B | $5.5B | $10.37B | $9.17B | $4.59B | $5.25B | $4.57B | $4.69B | $4.98B | $4.95B | $5.09B | $5.5B |
| QoQ Change | — | +12.5% | +22.2% | -3.0% | +9.4% | +0.0% | -11.4% | -32.3% | +100.0% | +31.0% | +88.6% | -11.6% | -49.9% | +14.3% | -12.9% | +2.5% | +6.3% | -0.7% | +2.8% | +8.2% |
| YoY Change | — | — | — | — | +45.8% | +29.6% | -6.1% | -34.4% | +20.0% | +57.1% | +234.6% | +336.6% | +9.3% | -4.6% | -55.9% | -48.9% | +8.5% | -5.7% | +11.3% | +17.5% |
Range$2.1B – $10.37B
CAGR+19.1%
Avg YoY Growth+38.4%
Median YoY Growth+10.3%
Current Streak2 quarters growth
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's cash & equivalents?
- Vertex Pharmaceuticals (VRTX) reported cash & equivalents of $5.5B in Q1 2026.
- How has Vertex Pharmaceuticals's cash & equivalents changed year-over-year?
- Vertex Pharmaceuticals's cash & equivalents increased by 17.5% year-over-year, from $4.69B to $5.5B.
- What is the long-term trend for Vertex Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's cash & equivalents has grown at a 12.7% compound annual growth rate (CAGR), from $2.8B to $5.09B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has available for immediate use.